ONCOLIN THERAPEUTICS ANNOUNCES THE DISCOVERY OF A NEW MORE EFFECTIVE ANTI-CANCER TREATMENT IN EXPERIMENTAL BRAIN TUMOR MODELS!   

According to a recent press release, a team of scientists supported by an Oncolin sponsored research agreement ( SRA ) and lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) has discovered a new inhibitor of glycolysis, which is superior to the other known inhibitors. These results were confirmed both in vitro as well as in vivo brain tumor models. These new results have demonstrated that the compound that Oncolin in collaboration with UTMDACC are currently developing clearly displays significantly better pharmacokinetics, increased potency and efficacy.

TechPrecision Corporation (OTCBB: TPCS), is certainly a stock to watch. A leading manufacturer of large-scale, high-precision machined metal fabrications for the alternative energy, medical, nuclear, defense, aerospace and other commercial industries, recently reported strong financial results for the fourth quarter and year ended March 31, 2008.


    * Net sales increased 64.5% to $9.3 million
    * Gross profit rose 185.6% to $2.6 million
    * Gross profit margin was 27.8%
    * Operating income increased 396.1% to $2.1 million
    * Net income increased to $853,000 compared to a loss of $8,000
    * Net income allocated to common stock increased to $853,000 from a loss of    $296,000
    * Net income per common share was $0.07 and $0.03 basic and diluted, versus $(0.03) per share basic and diluted the previous year